Clinical Research Directory
Browse clinical research sites, groups, and studies.
OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
Sponsor: Olivia Newton-John Cancer Research Institute
Summary
This is a first-in-human Phase 1 two-part, open-label, multi-center, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and maximum tolerated dose (MTD) of CT-179 in patients with recurrent glioblastoma and newly diagnosed MGMT-unmethylated glioblastoma who are eligible to receive radiation therapy following surgery, and to establish the recommended Phase 2 dose.
Official title: A Phase 1, Two-Part, Accelerated Dose Titration Trial of CT-179 as Monotherapy in the Treatment of Recurrent Glioblastoma and in Combination With Radiation Therapy in the Treatment of Newly Diagnosed MGMT-Unmethylated Glioblastoma
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
54
Start Date
2026-12
Completion Date
2028-09
Last Updated
2026-10-28
Healthy Volunteers
No
Interventions
CT-179
Daily administration of CT-179
Locations (6)
St Vincent's Hospital
Sydney, New South Wales, Australia
Royal North Shore Hospital
Sydney, New South Wales, Australia
Princess Alexandra Hospital
Brisbane, Queensland, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Austin Health
Heidelberg, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia